Showing results (161-170 of 208) with videos related to

Sort By:
Pageof 21
The Journal of Liquid Biopsy|March 3, 2025
Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experienceClaudia Parisi, José Carlos Benitez, Hélène Lecourt, et al.
The Lancet. Oncology|April 14, 2018
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 studyAntoine Italiano, Jean-Charles Soria, Maud Toulmonde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trialJean-Marie Michot, Serge Bologna, Jean-Noël Bastie, et al.
Science Translational Medicine|September 24, 2025
CAR T cell-mediated bone marrow inflammation causes hematotoxicity and favors clonal hematopoiesisMyriam Ben Khelil, Ahmadreza Arbab, Janesa Srikanthan, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2024
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive reviewArthur Géraud, Thomas Hueso, Ariane Laparra, et al.
Targeted Oncology|April 29, 2024
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 StudyMichael Maris, Gilles Salles, Won Seog Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|January 10, 2025
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignanciesVincent Ribrag, Lara Iglesias, Filippo De Braud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2019
Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly TrialHanneke C Kluin-Nelemans, Eva Hoster, Olivier Hermine, et al.
Ejhaem|July 18, 2022
Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphomaVincent Ribrag, Julio C Chavez, Carola Boccomini, et al.
Investigational New Drugs|June 10, 2017
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trialsJean-Marie Michot, Lina Benajiba, Laura Faivre, et al.
Pageof 21